Japan approves treprostinil for PAH

United Therapeutics Corp. (NASDAQ:UTHR) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved subcutaneous and IV Treprost treprostinil to treat pulmonary arterial hypertension (PAH). Mochida Pharmaceutical Co. Ltd. (Tokyo:4534) will commercialize the drug in Japan, with a pricing decision from Japan's National Health Insurance (NHI) expected in two to three months and a launch planned for later this year. United Therapeutics already markets the formulations as Remodulin in 37 countries, including the U.S. and most countries in the EU. ...